Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Herrmann, R; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B; Köhne, CH; Mingrone, W; Stemmer, SM; Tàmas, K; Kornek, GV; Koeberle, D; Cina, S; Bernhard, J; Dietrich, D; Scheithauer, W; ... (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology, 25(16), pp. 2212-7. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.09.0886

Full text not available from this repository. (Request a copy)

This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap) versus single-agent Gem in advanced/metastatic pancreatic cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bernhard, Jürg

ISSN:

0732-183X

ISBN:

17538165

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:53

Last Modified:

17 Mar 2015 21:57

Publisher DOI:

10.1200/JCO.2006.09.0886

PubMed ID:

17538165

Web of Science ID:

000247010400012

URI:

https://boris.unibe.ch/id/eprint/22395 (FactScience: 34517)

Actions (login required)

Edit item Edit item
Provide Feedback